Jaguar Health Competitors

Jaguar Health (NASDAQ:JAGX) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Jaguar Health and Veru's gross revenue, earnings per share (EPS) and valuation.

Veru has higher revenue and earnings than Jaguar Health. Veru is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Jaguar Health and Veru's net margins, return on equity and return on assets.

Volatility & Risk

Jaguar Health has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Veru has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jaguar Health and Veru, as provided by MarketBeat.

Veru has a consensus target price of $19.20, indicating a potential upside of 110.30%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Jaguar Health.

Insider & Institutional Ownership

1.4% of Jaguar Health shares are owned by institutional investors. Comparatively, 23.3% of Veru shares are owned by institutional investors. 3.2% of Jaguar Health shares are owned by company insiders. Comparatively, 26.1% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Veru beats Jaguar Health on 10 of the 13 factors compared between the two stocks.

Jaguar Health (NASDAQ:JAGX) and Chinook Therapeutics (NASDAQ:KDNY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jaguar Health and Chinook Therapeutics, as provided by MarketBeat.

Chinook Therapeutics has a consensus target price of $30.3333, indicating a potential upside of 101.68%. Given Chinook Therapeutics' higher probable upside, analysts clearly believe Chinook Therapeutics is more favorable than Jaguar Health.

Profitability

This table compares Jaguar Health and Chinook Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

1.4% of Jaguar Health shares are owned by institutional investors. 3.2% of Jaguar Health shares are owned by company insiders. Comparatively, 5.9% of Chinook Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Jaguar Health and Chinook Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Jaguar Health has higher earnings, but lower revenue than Chinook Therapeutics. Chinook Therapeutics is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jaguar Health has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Chinook Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.

Summary

Chinook Therapeutics beats Jaguar Health on 9 of the 13 factors compared between the two stocks.

Gossamer Bio (NASDAQ:GOSS) and Jaguar Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

72.0% of Gossamer Bio shares are owned by institutional investors. Comparatively, 1.4% of Jaguar Health shares are owned by institutional investors. 23.3% of Gossamer Bio shares are owned by company insiders. Comparatively, 3.2% of Jaguar Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Gossamer Bio and Jaguar Health, as reported by MarketBeat.com.

Gossamer Bio presently has a consensus price target of $23.00, suggesting a potential upside of 177.44%. Given Gossamer Bio's higher possible upside, research analysts clearly believe Gossamer Bio is more favorable than Jaguar Health.

Risk & Volatility

Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Jaguar Health has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500.

Earnings and Valuation

This table compares Gossamer Bio and Jaguar Health's gross revenue, earnings per share and valuation.

Jaguar Health has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gossamer Bio and Jaguar Health's net margins, return on equity and return on assets.

Summary

Gossamer Bio beats Jaguar Health on 8 of the 12 factors compared between the two stocks.

Rigel Pharmaceuticals (NASDAQ:RIGL) and Jaguar Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Valuation & Earnings

This table compares Rigel Pharmaceuticals and Jaguar Health's revenue, earnings per share and valuation.

Jaguar Health has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Rigel Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Jaguar Health has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Rigel Pharmaceuticals and Jaguar Health, as reported by MarketBeat.com.

Rigel Pharmaceuticals presently has a consensus target price of $8.3333, suggesting a potential upside of 130.84%. Given Rigel Pharmaceuticals' higher possible upside, research analysts plainly believe Rigel Pharmaceuticals is more favorable than Jaguar Health.

Profitability

This table compares Rigel Pharmaceuticals and Jaguar Health's net margins, return on equity and return on assets.

Institutional & Insider Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 1.4% of Jaguar Health shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 3.2% of Jaguar Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Rigel Pharmaceuticals beats Jaguar Health on 9 of the 13 factors compared between the two stocks.

Jaguar Health (NASDAQ:JAGX) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Jaguar Health and Albireo Pharma's top-line revenue, earnings per share (EPS) and valuation.

Jaguar Health has higher earnings, but lower revenue than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jaguar Health has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Jaguar Health and Albireo Pharma, as provided by MarketBeat.com.

Albireo Pharma has a consensus price target of $72.00, indicating a potential upside of 128.64%. Given Albireo Pharma's higher probable upside, analysts plainly believe Albireo Pharma is more favorable than Jaguar Health.

Profitability

This table compares Jaguar Health and Albireo Pharma's net margins, return on equity and return on assets.

Institutional and Insider Ownership

1.4% of Jaguar Health shares are held by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are held by institutional investors. 3.2% of Jaguar Health shares are held by insiders. Comparatively, 5.0% of Albireo Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Albireo Pharma beats Jaguar Health on 9 of the 13 factors compared between the two stocks.

Jaguar Health (NASDAQ:JAGX) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Jaguar Health and AnaptysBio, as provided by MarketBeat.com.

AnaptysBio has a consensus price target of $30.2857, indicating a potential upside of 37.60%. Given AnaptysBio's higher probable upside, analysts plainly believe AnaptysBio is more favorable than Jaguar Health.

Valuation & Earnings

This table compares Jaguar Health and AnaptysBio's top-line revenue, earnings per share (EPS) and valuation.

Jaguar Health has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

1.4% of Jaguar Health shares are held by institutional investors. 3.2% of Jaguar Health shares are held by insiders. Comparatively, 13.0% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Jaguar Health has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500.

Profitability

This table compares Jaguar Health and AnaptysBio's net margins, return on equity and return on assets.

Summary

AnaptysBio beats Jaguar Health on 9 of the 13 factors compared between the two stocks.